Gentium Announces Presentation Of Defibrotide Data At The American Society Of Hematology

VILLA GUARDIA, Italy, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide will be presented at the 52 nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

Poster session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Poster II, Hall A3/A4, Monday, December 6, 2010, 6:00 PM - 8:00 PM

"Meta-analysis of Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with comparison to a Historical Control (HC)" (Poster Board III-260). P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

"Safety of Defibrotide (DF) in Stem Cell Transplant (SCT) patients (Pts)" (Poster Board III-261). S. Corbacioglu et al., University of Regensburg, Regensburg, Germany.

Oral session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Transplant Related Toxicities, Room 110A, Tuesday, December 7, 2010, 8:45 AM

"Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): results of a treatment IND expanded access protocol" (Abstract #906), P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

For more details on the congress, please visit the official congress web site:

http://www.hematology.org/Meetings/Annual-Meeting/

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."
CONTACT:  Gentium S.p.A.          Salvatore Calabrese, Senior Vice President, Finance          +39 031-385-287          scalabrese@gentium.it          The Trout Group          Marcy Nanus          +1 646-378-2927          mnanus@troutgroup.com

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX